Table 3 Use of the 2013 guidelines for the appropriate use of G-CSFs, version 2, published by the JSCO
n = 301 | |
|---|---|
Q9. Do you know the JSCO guidelines are available on the web? | |
Yes | 228 (75.7)a |
No | 73 (24.3) |
Q10. How did you learn that the JSCO guidelines are available on a web? (multiple choice) | |
Academic meeting, study group meeting, workshop | 182 (60.5) |
Medical personnel | 118 (39.2) |
Academic journal, article | 21 (7.0) |
Website | 124 (41.2) |
Drug industry | 44 (14.6) |
Others | 3 (1.0) |
Q11. Are the JSCO guidelines useful for the actual work of pharmacists? | |
Very useful | 168 (55.8) |
Useful to some extent | 127 (42.2) |
Not so useful | 6 (2.0) |
Useless | 0 (0.0) |
Q12. How often do you refer to the JSCO guidelines? | |
Always | 34 (11.3) |
Usually | 121 (40.2) |
Sometimes | 131 (43.5) |
Seldom | 15 (5.0) |
Q13. Is there any difference between JSCO guideline and the actual work of pharmacists? | |
Not at all | 125 (41.6) |
Somewhat different | 162 (53.8) |
Considerably difference | 13 (4.3) |
Completely different | 1 (0.3) |
Q14. To the Q13. which chose “it is totally considerably slightly different with the difference with the difference” by a question. What kind of difference was it? | |
Usage of the prophylaxic administration of G-CSFs | 23 |
A pharmacist is not involved in the administration of G-CSFs | 19 |
It is difficult to fit a real patient | 15 |
Usage of no exothermicity neutropenia | 11 |
There is not consensus in the nosocomial G-CSFs usage | 9 |
The update of guidelines is late | 5 |
It is different from the usage of the package insert | 5 |
About the risk classification of the cancer chemotherapy regimen | 4 |
Usage of the remedial dosage | 4 |
Others | 11 |